15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Height and weight development following cyclical intravenous pamidronate in children and adolescents with chronic recurrent multifocal osteomyelitis (CRMO)

      abstract

      , 1 , 1 , 1

      Pediatric Rheumatology Online Journal

      BioMed Central

      15th Paediatric Rheumatology European Society (PreS) Congress

      14-17 September 2008

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives Treatment with cyclical intravenous pamidronate (IVP) improves clinical course in children with chronic recurrent multifocal osteomyelitis (CRMO), but theoretically might affect longitudinal growth. In this study we analyzed growth during IVP treatment in ten CRMO patients. Methods 10 patients (5 M, 5 F) were enrolled, with mean (range) age 11.4 (4.5–16.3) years at IVP treatment. All patients received a 3-day infusion of IVP (0.5 mg/kg/day for the first dose; 1 mg/kg/day subsequently), followed by 1-day infusion monthly or 3-day infusion every 3 months until resolution of MRI documented bone inflammation. Weight and height were measured prior to first IVP, at 1-year, and at final follow-up, and results were transformed into age- and gender-matched z-scores. Hotelling's test on the bivariate height and weight differences between 2 time points was performed. Results Patients received a mean (range) 6.23 (2.5–11.5) mg/kg/year of IVP to achieve resolution of MRI documented inflammation. Follow-up was a mean (range) 27.4 (16–46) months. At baseline, 4/10 children had low baseline height z-scores (z < -1.0), compared to 1/10 at final follow-up. At one year, height and weight z-scores jointly had increased significantly (p = 0.014). Univariate point estimates and 95% confidence intervals (95% CI) for average differences post-pre were height = 0.192, (95% CI-0.16, 0.54), and weight = 0.574, (95% CI 0.10, 1.04). Conclusion At 1-year following first pamidronate treatment, age-and gender-specific height and weight z-scores remained similar or increased, suggesting that 1. Pamidronate in pediatric CRMO does not have a detrimental effect on longitudinal growth "Catch-up growth" can occur in this selected population.

          Related collections

          Author and article information

          Conference
          Pediatr Rheumatol Online J
          Pediatr Rheumatol Online J
          Pediatric Rheumatology Online Journal
          BioMed Central
          1546-0096
          2008
          15 September 2008
          : 6
          : Suppl 1
          : P187
          Affiliations
          [1 ]University of Calgary, Calgary, Alberta, Canada
          Article
          1546-0096-6-S1-P187
          10.1186/1546-0096-6-S1-P187
          3333989
          Copyright ©2008 Miettunen et al; licensee BioMed Central Ltd.
          15th Paediatric Rheumatology European Society (PreS) Congress
          London, UK
          14-17 September 2008
          Categories
          Poster Presentation

          Pediatrics

          Comments

          Comment on this article